Nuveen Asset Management, LLC Nektar Therapeutics Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 326,716 shares of NKTR stock, worth $7.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

326,716

Previous 326,716 -0.0%

Holding current value

$7.71 Million

Previous $424,000 28.54%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.11 - $1.48 $25,739 - $34,319	-23,189 Reduced 6.63%	326,716 $424,000
Q2 2024 Aug 09, 2024	BUY	$0.9 - $1.83 $314,914 - $640,326	349,905 New	349,905 $433,000
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $34,297 - $168,808	-53,590 Reduced 9.54%	508,137 $355,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $173,979 - $366,813	-85,704 Reduced 13.24%	561,727 $1.27 Million
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $38,750 - $65,519	-12,747 Reduced 1.93%	647,431 $2.07 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $635,328 - $1.24 Million	200,419 Added 43.59%	660,178 $2.51 Million
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $22,272 - $73,456	-5,354 Reduced 1.15%	459,759 $2.62 Million
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $266,125 - $452,388	-24,573 Reduced 5.02%	465,113 $6.28 Million
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $353,412 - $509,433	-27,040 Reduced 5.23%	489,686 $8.79 Million
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $67,186 - $82,966	-4,067 Reduced 0.78%	516,726 $8.87 Million
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $272,395 - $418,791	-16,449 Reduced 3.06%	520,793 $10.4 Million
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $42,373 - $51,133	2,687 Added 0.5%	537,242 $9.13 Million
Q3 2020 Nov 16, 2020	SELL	$16.59 - $24.79 $118,220 - $176,653	-7,126 Reduced 1.32%	534,555 $8.87 Million
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $628,608 - $873,936	-37,284 Reduced 6.44%	541,681 $12.5 Million
Q1 2020 May 14, 2020	BUY	$14.47 - $27.96 $3.47 Million - $6.71 Million	240,071 Added 70.84%	578,965 $10.3 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $3.15 Million - $4.59 Million	-198,454 Reduced 36.93%	338,894 $7.32 Million
Q3 2019 Nov 14, 2019	SELL	$16.91 - $36.27 $6.75 Million - $14.5 Million	-399,415 Reduced 42.64%	537,348 $9.79 Million
Q2 2019 Aug 15, 2019	BUY	$31.0 - $36.3 $29 Million - $34 Million	936,763 New	936,763 $33.3 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $117,551 - $218,838	-3,863 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $179,474 - $264,576	3,863 New	3,863 $235,000
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $1.24 Million - $2.8 Million	-26,849 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $1.1 Million - $2.08 Million	19,227 Added 252.26%	26,849 $2.85 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $5.2 Million - $13.7 Million	-225,950 Reduced 96.74%	7,622 $0
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $4.16 Million - $5.61 Million	233,572	233,572 $5.61 Million

Others Institutions Holding NKTR

# of Institutions

Shares Held

16.8M

Call Options Held

17.2K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $4.42B
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Nektar Therapeutics Transaction History